GeoVax Labs Inc. (NASDAQ:GOVX) Short Interest Down 61.9% in July

GeoVax Labs Inc. (NASDAQ:GOVX) was the recipient of a significant decline in short interest during the month of July. As of July 31st, there was short interest totaling 57,276 shares, a decline of 61.9% from the July 15th total of 150,485 shares. Based on an average daily volume of 220,342 shares, the short-interest ratio is presently 0.3 days. Approximately 1.7% of the shares of the stock are short sold.

Analyst Ratings Changes

Several brokerages have recently commented on GOVX. Wall Street Zen upgraded GeoVax Labs from a “sell” rating to a “hold” rating in a research report on Sunday, June 21st. Weiss Ratings restated a “sell (e+)” rating on shares of GeoVax Labs in a research report on Friday, July 17th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, GeoVax Labs currently has a consensus rating of “Reduce” and a consensus target price of $150.00.

GeoVax Labs Stock Up 0.0%

Shares of GeoVax Labs stock traded up $0.00 on Friday, hitting $0.72. The stock had a trading volume of 197,033 shares, compared to its average volume of 186,596. GeoVax Labs has a one year low of $0.64 and a one year high of $20.00. The stock’s 50-day simple moving average is $1.03 and its two-hundred day simple moving average is $1.53. The stock has a market cap of $2.49 million, a price-to-earnings ratio of -0.06 and a beta of 3.73.

GeoVax Labs (NASDAQ:GOVX) last posted its quarterly earnings results on Monday, July 27th. The company reported ($0.97) EPS for the quarter, beating analysts’ consensus estimates of ($2.16) by $1.19. As a group, equities analysts predict that GeoVax Labs will post -4.94 EPS for the current fiscal year.

Hedge Funds Weigh In On GeoVax Labs

Several hedge funds and other institutional investors have recently modified their holdings of the company. Ieq Capital LLC bought a new stake in shares of GeoVax Labs in the second quarter worth about $1,352,000. NFJ Investment Group LLC purchased a new position in GeoVax Labs during the 2nd quarter valued at about $1,419,000. Rice Hall James & Associates LLC bought a new position in GeoVax Labs during the 2nd quarter valued at approximately $1,888,000. Man Group plc bought a new position in GeoVax Labs during the 2nd quarter valued at approximately $2,396,000. Finally, Jane Street Group LLC purchased a new stake in GeoVax Labs in the 1st quarter worth approximately $27,000. 6.09% of the stock is owned by institutional investors.

GeoVax Labs Company Profile

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.